BioCentury | Oct 7, 2013
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Wk 10/4 Company Bank Analyst Coverage Opinion chg cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Downgrade Neutral (from outperform) -62% $2.72 Deutsche Bank Alethia Young Downgrade Hold (from buy) Piper...
BioCentury | May 25, 2009
Regulation

PDX coverage gap

The future of the U.S. diagnostics industry, and hopes that personalized medicine can be transformed from a slogan into reality, hinge in large measure on payers learning to discern which genetic tests provide clinically valuable...
BioCentury | Jul 7, 2008
Strategy

Flurizan’s failure adds value

Myriad Genetics Inc. and partner H. Lundbeck A/S were surely disappointed when Flurizan tarenflurbil failed a Phase III trial to treat mild Alzheimer’s disease. But investors made it very clear that they would rather the...
BioCentury | Apr 19, 2004
Company News

Myriad Genetics, University of Wales deal

The university's Institute of Medical Genetics granted MYGN exclusive U.S. rights to detect mutations in Mut Y Homolog (MYH), a DNA repair gene implicated in colon cancer. MYGN will add MYH detection to its Colaris...
BioCentury | May 20, 2002
Company News

Myriad Genetics sales and marketing update

MYGN launched Colaris AP predictive medicine product to determine a patient's risk of hereditary colon cancer. The product detects mutations in the APC gene , which cause familial adenomatous polyposis (FAP) and attenuated FAP, both of...
BioCentury | Dec 10, 2001
Company News

Myriad Genetics, Laboratory Corp. of America Holdings sales and marketing update

MYGN granted LH exclusive sales and distribution rights to MYGN's predictive medicine products. For an upfront fee, LH will receive the right to market to primary care physicians MYGN's BRACAnalysis , Colaris, Melaris and CardiaRisk tests...
BioCentury | Oct 23, 2000
Company News

Myriad Genetics, MDS sales and marketing update

MDS expanded its exclusive marketing agreement with MYGN to include marketing in Canada of MYGN's Colaris diagnostic that detects mutations in two genes with predictive value for hereditary colorectal and uterine cancer. MDS exclusively markets...
BioCentury | Oct 2, 2000
Company News

Myriad Genetics sales and marketing update

MYGN launched its Colaris test that detects mutations in MLH1 and MSH2 genes associated with hereditary colorectal and uterine cancer. Myriad Genetics Inc. (MYGN), Salt Lake City, Utah Business: Diagnostics/Imaging WIR Staff cancer Diagnostic...
BioCentury | Aug 28, 2000
Company News

Genzyme Molecular, Myriad Genetics deal

GZMO granted MYGN a non-exclusive license to an undisclosed gene related to hereditary colon cancer. MYGN will detect mutations in the gene and in a second gene that is not part of the GZMO deal...
BioCentury | Aug 24, 2000
Company News

Genzyme Molecular licensing deal with Myriad

GZMO granted MYGN a non-exclusive license to an undisclosed gene related to hereditary colon cancer. MYGN will use this gene, and a second gene that is not part of the GZMO deal, in its Colaris...
Items per page:
1 - 10 of 11